Results 91 to 100 of about 2,175,372 (155)

Efficacy and Safety of Co‐Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck‐001): A Phase II Trial

MedComm, Volume 7, Issue 10, October 2026.
Liver metastasis is a key driver of immune tolerance in patients with melanoma receiving immune checkpoint inhibitor therapy. This single‐arm phase II trial prospectively investigated the efficacy and safety of co‐ablation combined with sintilimab for liver metastatic melanoma.
Lujun Shen, Letao Lin, Shuanggang Chen, Chen Li, Ruizhi Tang, Lin Xie, Yujia Wang, Yunpeng Li, Hongliang Zou, Dandan Li, Xiaoshi Zhang, Weijun Fan   +11 more
wiley   +1 more source

Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib

Advanced Science
Drug resistance remains a major hurdle for the therapeutic efficacy of lenvatinib in hepatocellular carcinoma (HCC). However, the underlying mechanisms remain largely undetermined.
Runyu Dong, Yao Fei, Yiren He, Peng Gao, Bo Zhang, Menglin Zhu, Zhixiong Wang, Longfei Wu, Shuai Wu, Xiaoming Wang, Juan Cai, Zhiqiang Chen, Xueliang Zuo   +12 more
doaj   +1 more source

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met

Journal of Hepatocellular Carcinoma, 2022
Xin Xu,1,2 Wenjing Jiang,1 Peng Han,1 Jingyan Zhang,3 Liquan Tong,3 Xueying Sun1 1Hepatosplenic Surgery Center, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People’s Republic of China; 2Department of General Surgery, Daqing
Xu X, Jiang W, Han P, Zhang J, Tong L, Sun X   +5 more
doaj  

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2619-2635, October 2026.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Iron Homeostasis and Liver Diseases

Journal of Cellular and Molecular Medicine, Volume 30, Issue 20, October 2026.
ABSTRACT Iron is an essential micronutrient whose ability to cycle between ferric (Fe3+) and ferrous (Fe2+) states makes it crucial for physiological processes, including oxygen transport, DNA synthesis, and oxidative phosphorylation. However, because both deficiency and excess can cause severe pathology, precise regulation is critical. The liver plays
Peng Yang, Zhitian Shi, Qin Huang, Zhihong Tu, Yue Sun, Lin Wang, Yonglong Wei   +6 more
wiley   +1 more source

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

, 2019
Nicola Personeni,1,2 Tiziana Pressiani,1 Lorenza Rimassa1 1Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center – IRCCS, Rozzano 20089, Milan, Italy; 2Department of Biomedical Sciences, Humanitas ...
Personeni N, Rimassa L, Pressiani T
core  

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial

Lenvatinib, a multi-kinase inhibitor, has been approved as first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is limited.
Dan Cui, Weiping Zhou, Haojie Jin, Yaoping Shi, Lei Xia, Donghua Shi, Zhen Sun, Jiachang Chi, Siying Wang, Wu Yang, Tao Wang, Rene Bernards, Guangxin Jin, Qi Jia, Zicheng Lv, Yan Lin, Jiaojiao Zheng, Meng Li, Shengxian Yuan, Bo Zhai, Xiaoyin Tang, Hao Feng, Fan Yang, Wenxin Qin   +23 more
core   +1 more source

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

, 2017
Alessandro Leonetti, Francesco Leonardi, Melissa Bersanelli, Sebastiano Buti Medical Oncology Unit, University Hospital of Parma, Parma, Italy Introduction: Renal cell carcinoma (RCC) represents 2%–3% of all cancers in adults, and its ...
Leonetti A, Bersanelli M, Buti S., Leonetti A., Leonardi F., Bersanelli M., Leonardi F, Buti S   +7 more
core   +1 more source